Newsroom
- Press Release
15 March 24
CuraTeQ Biologics successfully completes Phase 1 trial for Omalizumab biosimilar
Read more - Press Release
17 February 24
Auro Peptides completes US FDA inspection with zero observations
Read more - Press Release
17 January 24
CuraTeQ Biologics’ Trastuzumab Biosimilar receives recommendation for marketing authorization in India
Read more - Press Release
20 November 23
CuraTeQ Biologics eyes ‘WuXi’ moment to kickstart Indian bio-CDMO sector
Read more - Press Release
10 July 23
CuraTeQ Biologics to market Ustekinumab biosimilar to treat Crohn’s disease, arthritis
Read more - Press Release
05 July 23
CuraTeQ Biologics announces positive Phase-3 results for Trastuzumab biosimilar
Read more